Contemporary Management of HIV 2021

Gain expert insights on the latest data supporting contemporary HIV prevention and HIV treatment across settings, including patients who are newly diagnosed, virologically suppressed, or experiencing virologic failure with resistance, along with new and emerging ART strategies.
Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD, FIDSA, MACP
Program Director
Roger Bedimo, MD, MS, FACP
Eric S. Daar, MD
Joseph J. Eron, Jr., MD
Jason Halperin, MD, MPH
Princy N. Kumar, MD, FIDSA, MACP
Daniel R. Kuritzkes, MD
Paul E. Sax, MD
Babafemi Taiwo, MBBS

ART for Complex Cases

Download this expert-authored slideset to review treatment strategies for complex HIV cases; topics include managing heavily treatment-experienced patients, modifying ART in patients with underlying ARV resistance, and considerations for first-line ART selection in patients with obesity.

Eric S. Daar, MD Joseph J. Eron, Jr., MD Princy N. Kumar, MD, FIDSA, MACP Released: September 1, 2020

Gain expert insights on treatment strategies for complex HIV cases; topics include managing ART in heavily treatment-experienced patients, modifying ART in patients with underlying ARV resistance, and considerations for first-line ART selection in patients with obesity.

Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD, FIDSA, MACP
Program Director
Eric S. Daar, MD Jason Halperin, MD, MPH
Physicians: maximum of 1.25 AMA PRA Category 1 Credits Registered Nurses: 1.25 Nursing contact hours Pharmacists: 1.25 contact hours (0.125 CEUs) Released: December 8, 2020 Expired: December 7, 2021

Emerging Approaches to Optimize ART

Download this expert-authored slideset to consider important clinical questions related to first-line ART, switch strategies for patients with virologic suppression, and use of antiretroviral drugs to prevent HIV infection, with an emphasis on the role of new and emerging strategies.

Joseph J. Eron, Jr., MD Princy N. Kumar, MD, FIDSA, MACP Paul E. Sax, MD Released: August 28, 2020

Gain expert insights on important clinical questions related to first-line ART, switch strategies for patients with virologic suppression, and use of antiretroviral drugs to prevent HIV infection, with an emphasis on the role of new and emerging strategies.

Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD, FIDSA, MACP
Program Director
Daniel R. Kuritzkes, MD Paul E. Sax, MD
Physicians: maximum of 1.25 AMA PRA Category 1 Credits Registered Nurses: 1.25 Nursing contact hours Pharmacists: 1.25 contact hours (0.125 CEUs) Released: December 30, 2020 Expired: December 29, 2021

Heavily Treatment-Experienced Patients

Download this expert-authored slideset to review guidelines and key data on assessing virologic failure and current management options for patients with multiclass drug resistance experiencing treatment failure.

Joseph J. Eron, Jr., MD Princy N. Kumar, MD, FIDSA, MACP Released: October 20, 2020

Gain expert insights on treatment strategies for heavily treatment–experienced patients with HIV. Topics include assessment of virologic failure, current treatment options for patients with multiclass drug resistance, and guidance on selecting the next line of therapy for patients experiencing virologic failure due to resistance.

Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD, FIDSA, MACP
Program Director
Roger Bedimo, MD, MS, FACP Jason Halperin, MD, MPH
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: December 22, 2020 Expired: December 21, 2021

Individualizing First line ART

Download this expert-authored slideset to review national guidelines, key study data, and individual considerations for optimizing the use of current ART regimens as initial HIV treatment and in switch strategies for patients with viral suppression who require a change in therapy.

Joseph J. Eron, Jr., MD Princy N. Kumar, MD, FIDSA, MACP Babafemi Taiwo, MBBS Released: July 6, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue